3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Withdrawn
2
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
Lung Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Colonic Neoplasms
1
Interventions
Cisplatin
9
pembrolizumab
7
Radiosurgery
6
Gemcitabine
6
Paclitaxel
5
Dexamethasone
5
Taxes
4
Carboplatin
4
trametinib
3
ibrutinib
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Fluorouracil
3
Erlotinib Hydrochloride
3
Blood Specimen Collection
3
Ascorbic Acid
3
venetoclax
2
veliparib
2
tocilizumab
2
pazopanib
2
obinutuzumab
2
naquotinib
2
lenvatinib
2
fludarabine
2
enzalutamide
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT02947113
2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2
Withdrawn
NCT01936961
2017-06-27
I-CREST
Western Regional Medical Center
Phase NA
Withdrawn